PsA Risk Similar With IL-23 and IL-12/23 Inhibitors

TOPLINE:

In a retrospective cohort study, treatment with an IL-23 inhibitor was associated with a similar incidence of psoriatic arthritis (PsA) as treatment with IL-2/23 inhibitors in patients with psoriasis.

METHODOLOGY:

• In the study, researchers evaluated adults with psoriasis (average age, 46 years) in the TriNetX research network.
• Patients received either an IL-23 inhibitor (n = 2273; guselkumab, tildrakizumab, or risankizumab) or an IL-12/23 inhibitor (n = 2995; ustekinumab).
• The study outcome was the onset of PsA.

TAKEAWAY:

• In propensity matched cohorts, the risk for PsA was not statistically different among patients treated with an IL-23 inhibitor and those treated with an IL-12/23 inhibitor (hazard ratio, 0.96; P = .812).
• No statistically significant differences in risk between the two groups were seen in demographic subgroups, although sample sizes were small.
• The cumulative incidence of PsA was not significantly different between the two groups (P = .812), with the IL-23 inhibitor–treated cohort showing marginally higher rates between years 3 and 5.

IN PRACTICE:

The results underscore the “comparable efficacy” of IL-23 and IL-12/23 inhibitors for patients with psoriasis, the authors wrote, adding that more research with larger cohorts and longer follow-ups “is essential to further our understanding of these therapies’ long-term effectiveness.” 

SOURCE:

The study, led by Sung Huang Laurent Tsai, MD, MPH, Chang Gung Memorial Hospital, Keelung, Taiwan, was published online on July 27, 2024, in the Journal of the American Academy of Dermatology.

LIMITATIONS:

Study limitations included misclassification and the retrospective design. The numbers of Black and Asian patients were small, limiting subgroup analysis.

DISCLOSURES:

The study was not supported by any funding sources. The authors declared no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.